Cambridge Investment Research Advisors
SAGE

Cambridge Investment Research Advisors’s Sage Therapeutics SAGE Stock Holding History

Cambridge Investment Research Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-27,432
Closed -$250K – 3844
2025
Q2 		$250K Hold
27,432
– – ﹤0.01% 3135
2025
Q1 		$218K Sell
27,432
-400
-1% -$2.93K ﹤0.01% 3133
2024
Q4 		$151K Sell
27,832
-716
-3% -$4.38K ﹤0.01% 3254
2024
Q3 		$206K Sell
28,548
-870
-3% -$7.96K ﹤0.01% 3134
2024
Q2 		$319K Sell
29,418
-1,937
-6% -$24.8K ﹤0.01% 2656
2024
Q1 		$588K Sell
31,355
-1,918
-6% -$44.2K ﹤0.01% 2154
2023
Q4 		$721K Sell
33,273
-1,800
-5% -$35.7K ﹤0.01% 1883
2023
Q3 		$722K Sell
35,073
-500
-1% -$14.4K ﹤0.01% 1789
2023
Q2 		$1.67M Sell
35,573
-666
-2% -$33.1K 0.01% 1283
2023
Q1 		$1.52M Sell
36,239
-192
-0.5% -$8.26K 0.01% 1301
2022
Q4 		$1.39M Buy
+36,431
New +$1.39M 0.01% 1299
2020
Q1 		– Sell
-3,477
Closed -$251K – 2448
2019
Q4 		$251K Buy
3,477
+1,168
+51% +$144K ﹤0.01% 2032
2019
Q3 		$324K Buy
2,309
+274
+13% +$45.8K ﹤0.01% 1764
2019
Q2 		$373K Buy
+2,035
New +$347K ﹤0.01% 1620

Other funds holding SAGE

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Cambridge Investment Research Advisors's SAGE Position: Q3 2025 in Review

Cambridge Investment Research Advisors sold out of Sage Therapeutics (SAGE) in Q3 2025, closing a stake of 27,432 shares — an estimated $250K sold.

Cambridge Investment Research Advisors first reported a position in SAGE in Q2 2019 and held it in 14 quarters. The position peaked at $1.67M in Q2 2023. 5 funds tracked by Wall St. Rank hold SAGE as of Q3 2025.

  • Cambridge Investment Research Advisors reported no remaining Sage Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 27,432 Sage Therapeutics shares in Q3 2025, an estimated $250K.
  • Cambridge Investment Research Advisors first reported a position in Sage Therapeutics in Q2 2019 and held it in 14 quarters.
  • Cambridge Investment Research Advisors's Sage Therapeutics position peaked at $1.67M in Q2 2023.
  • 5 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2025, filed 12 Nov 2025.